Definium Therapeutics, Inc. (DFTX)
38.68
+0.83
(+2.19%)
USD |
NASDAQ |
Sep 17, 16:00
38.60
-0.08
(-0.21%)
Pre-Market: 09:01
Definium Therapeutics Cash from Operations (Quarterly) : -52.33M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -52.33M |
| March 31, 2026 | -42.63M |
| December 31, 2025 | -41.89M |
| September 30, 2025 | -29.89M |
| June 30, 2025 | -30.64M |
| March 31, 2025 | -29.42M |
| December 31, 2024 | -23.88M |
| September 30, 2024 | -17.24M |
| June 30, 2024 | -19.73M |
| March 31, 2024 | -16.60M |
| December 31, 2023 | -19.80M |
| September 30, 2023 | -16.71M |
| June 30, 2023 | -13.94M |
| March 31, 2023 | -13.33M |
| December 31, 2022 | -11.45M |
| September 30, 2022 | -8.749M |
| June 30, 2022 | -15.01M |
| March 31, 2022 | -12.87M |
| December 31, 2021 |
| Date | Value |
|---|---|
| September 30, 2021 | -16.28M |
| June 30, 2021 | -11.92M |
| March 31, 2021 | -9.62M |
| December 31, 2020 | -8.211M |
| September 30, 2020 | -6.181M |
| June 30, 2020 | -5.396M |
| March 31, 2020 | -5.10M |
| August 31, 2019 | 0.0242M |
| May 31, 2019 | -0.2688M |
| February 28, 2019 | 0.0707M |
| November 30, 2018 | -0.0347M |
| August 31, 2018 | -0.1605M |
| May 31, 2018 | -0.1367M |
| February 28, 2018 | -0.2505M |
| November 30, 2017 | -0.1575M |
| August 31, 2017 | -0.1565M |
| May 31, 2017 | -0.0733M |
| February 28, 2017 | -0.2977M |
| November 30, 2016 | -0.1555M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | -2.536M |
| CNBX Pharmaceuticals, Inc. | -0.0477M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | -48.30M |
| Fulcrum Therapeutics, Inc. | -16.04M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -315.46M |
| Cash from Financing (Quarterly) | 758.70M |
| Free Cash Flow | -166.74M |
| Free Cash Flow Per Share (Quarterly) | -0.4728 |
| Free Cash Flow to Equity (Quarterly) | -48.03M |
| Free Cash Flow to Firm (Quarterly) | -51.10M |
| Free Cash Flow Yield | -4.27% |